Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?

Author:

Pecciarini Lorenza1,Brunetto Emanuela1,Grassini Greta1,De Pascali Valeria1,Ogliari Francesca Rita2,Talarico Anna1,Marra Giovanna1,Magliacane Gilda1,Redegalli Miriam1ORCID,Arrigoni Gianluigi1,Lazzari Chiara3,Gregorc Vanesa3,Bulotta Alessandra2,Doglioni Claudio1,Cangi Maria Giulia1ORCID

Affiliation:

1. Pathology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

2. Department of Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

3. Candiolo Cancer Institute, FPO-IRCCS, 10060 Turin, Italy

Abstract

The ability to identify the broadest range of targetable gene fusions is crucial to facilitate personalized therapy selection for advanced lung adenocarcinoma (LuADs) patients harboring targetable receptor tyrosine kinase (RTK) genomic alterations. In order to evaluate the most effective testing approach for LuAD targetable gene fusion detection, we analyzed 210 NSCLC selected clinical samples, comparing in situ (Fluorescence In Situ Hybridization, FISH, and ImmunoHistoChemistry, IHC) and molecular (targeted RNA Next-Generation Sequencing, NGS, and RealTime-PCR, RT-PCR) approaches. The overall concordance among these methods was high (>90%), and targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice, allowing the simultaneous analysis of a large set of genomic rearrangements at the RNA level. However, we observed that FISH was useful to detect targetable fusions in those samples with inadequate tissue material for molecular testing as well as in those few cases whose fusions were not identified by the RNA NGS panel. We conclude that the targeted RNA NGS analysis of LuADs allows accurate RTK fusion detection; nevertheless, standard methods such as FISH should not be dismissed, as they can crucially contribute to the completion of the molecular characterization of LuADs and, most importantly, the identification of patients as candidates for targeted therapies.

Publisher

MDPI AG

Subject

General Medicine

Reference23 articles.

1. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group;Mosele;Ann. Oncol.,2020

2. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology;Lindeman;Arch. Pathol. Lab. Med.,2018

3. Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications;Kazdal;Genes Chromosom. Cancer,2022

4. Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer;Carcereny;Cancer Treat. Rev.,2022

5. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population;Westphalen;NPJ Precis. Oncol.,2021

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3